BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38079023)

  • 21. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
    Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
    Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
    J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
    Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
    Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
    Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.
    Benhammou JN; Aby ES; Shirvanian G; Manansala K; Hussain SK; Tong MJ
    Sci Rep; 2020 Jun; 10(1):9902. PubMed ID: 32555268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
    Tavakoli H; Robinson A; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
    Dig Dis Sci; 2017 Aug; 62(8):2174-2181. PubMed ID: 28474143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.
    Paranaguá-Vezozzo DC; Ono SK; Alvarado-Mora MV; Farias AQ; Cunha-Silva M; França JI; Alves VA; Sherman M; Carrilho FJ
    Ann Hepatol; 2014; 13(4):386-93. PubMed ID: 24927609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Underrecognition and Suboptimal Quality of Care for Nonalcoholic Fatty Liver Disease Cirrhosis in Primary Care Patients with Diabetes Mellitus.
    Chu JN; Goldman ML; Brandman D; Sohn JH; Islam K; Ross LA; Fox RK
    Am J Med; 2024 Feb; 137(2):172-177.e2. PubMed ID: 37890572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.
    Ioannou GN; Green P; Lowy E; Mun EJ; Berry K
    PLoS One; 2018; 13(9):e0204412. PubMed ID: 30260995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.